Updated safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström’s macroglobulinemia

Molecule: Sonrotoclax

BGB-11417-103 Trial

BGB-11417-103 (NCT04771130) is a Phase 1b/2, open-label, dose-finding, and expansion study of sonrotoclax in patients with myeloid malignancies.

Reading
28 May 2025